Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 19/20 | 0.82 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.82 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.82 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.82 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL393158 | 0.90 | MAP2K1 (0.79) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL570183 | 0.90 | MAP2K1 (0.79) | MAP2K1MAP2K2MAP2K5EIF2AK1CYP2C9 | |
| SCHEMBL12295137 | 0.90 | MAP2K1 (0.79) | MAP2K1MAP2K2MAP2K5EIF2AK1CYP2C9 | |
| Azd-8330 SCHEMBL388533 | 0.90 | MAP2K1 (1.00) | MAP2K1MAP2K2MAP2K5EIF2AK1CYP2C9 | |
| Azd-8330 SCHEMBL29360392 | 0.90 | MAP2K1 (1.00) | MAP2K1MAP2K2MAP2K5EIF2AK1CYP2C9 | |
| SCHEMBL23187890 | 0.89 | MAP2K1 (0.68) | MAP2K1MAP2K2MAP2K5EIF2AK1CYP2C9 | |
| SCHEMBL392617 | 0.89 | MAP2K1 (0.77) | MAP2K1MAP2K2MAP2K5EIF2AK1CYP2C9 | |
| SCHEMBL19443280 | 0.88 | MAP2K1 (0.65) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL392252 | 0.87 | MAP2K1 (0.63) | MAP2K1MAP2K2MAP2K5EIF2AK1CYP2C9 | |
| SCHEMBL392066 | 0.82 | MAP2K1 (0.67) | MAP2K1MAP2K2MAP2K5EIF2AK1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230201198-A1 | METHODS OF TREATING ABNORMAL CELL GROWTH | RGCM SA LLC, AS PURCHASER AGENT | 2023-06-29 | — | — | US | disclosed |
| EP-3800471-A1 | COMPOSITION FOR PROMOTING DIFFERENTIATION OF AND PROTECTING NEURAL STEM CELLS AND METHOD FOR INDUCING NEURAL REGENERATION USING SAME | Genuv Inc. (KR) | 2021-04-07 | — | — | EP | disclosed |
| EP-3425390-B1 | COMPOSITION FOR PROMOTING DIFFERENTIATION OF AND PROTECTING NEURAL STEM CELLS AND METHOD FOR INDUCING NEURAL REGENERATION USING SAME | GENUV INC (KR) | 2020-12-23 | — | — | EP | disclosed |
| EP-3054992-B1 | PROTEIN-POLYMER-DRUG CONJUGATES | ASANA BIOSCIENCES LLC (US) | 2019-08-14 | — | — | EP | disclosed |
| EP-3054991-B1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS INC (US) | 2019-04-03 | — | — | EP | disclosed |
| EP-2928504-B1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS INC (US) | 2019-02-20 | — | — | EP | disclosed |
| EP-2931316-B1 | HYDROXYL-POLYMER-DRUG-PROTEIN CONJUGATES | MERSANA THERAPEUTICS INC (US) | 2019-02-20 | — | — | EP | disclosed |
| EP-3228325-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | Mersana Therapeutics, Inc. (US) | 2017-10-11 | — | — | EP | disclosed |
| WO-2017106492-A1 | COMBINATIONS FOR THE TREATMENT OF CANCER | IGNYTA, INC. (US) | 2017-06-22 | — | — | WO | disclosed |
| EP-2717916-B1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS INC (US) | 2017-03-08 | — | — | EP | disclosed |
| WO-2017033113-A1 | THERAPEUTIC COMBINATIONS OF A MEK INHIBITOR AND A BTK INHIBITOR | ACERTA PHARMA B.V. (NL) | 2017-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230201198-A1 | METHODS OF TREATING ABNORMAL CELL GROWTH | KRAS, NRAS, HRAS | MAP2K1 19/4885MAP2K2 27/4885MAP2K5 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.